Citations

Clear

4847 citation(s) found for "Yu, Eric".

PH Grand Rounds: Puzzling Etiology of Pulmonary Hypertension Resolved
Levine, Deborah J. , Fenstad, Eric R. , Bick, Benjamin L. , Frantz, Robert P.

Mayo Clinic

Advances in Pulmonary Hypertension | February 26, 2019 | Volume: 13 | Issue: 2 | Pages: 65-67

10.21693/1933-088x-13.2.65 Get It

Section editor's note: Welcome to a new section in Advances titled “Pulmonary Hypertension Grand Rounds” (PHGR), which we are introducing in this issue. With this addition, Advances offers a unique opportunity for trainees and junior faculty interested in pulmonary hypertension (PH). This section will highlight cases with literature reviews written by young clinicians and researchers in PH. PHGR was created to use patient cases to integrate individual clinical expertise with the best available evidence from the literature to enable the best decisions for patients. As with the rest of the journal, our audience continues to be physicians, researchers, nurses, students, residents, and fellows interested in both the care of individual patients and the advances in our field. We welcome comments about the section and inquiries regarding submitting a case for publication. Please direct inquiries to advancesgrandrounds@PHAssociation.org
Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer’s disease
Vöglein, Jonathan , Paumier, Katrina L. , Preische, Oliver, Hassenstab, Jason , Benzinger, Tammie L.S. , Noble, James M. , Berman, Sarah , Graff‐Radford, Neill R. , Farlow, Martin R. , Chhatwal, Jasmeer P. , Salloway, Stephen , Xiong, Chengjie , Cairns, Nigel J., Mori, Hiroshi , Masters, Colin L. , Goate, Alison , Buckles, Virginia, Fox, Nick C. , Chrem, Patricio, Allegri, Ricardo , Ringman, John M. , Höglinger, Günter U. , Steiner, Harald , Dieterich, Marianne , Haass, Christian , Laske, Christoph , Morris, John C. , Bateman, Randall J. , Danek, Adrian , Network, Dominantly Inherited Alzheimer, Höglinger, Günter U , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Benzinger, Tammie L S , Fox, Nick C , Hassenstab, Jason , Morris, John C , Jucker, Mathias , McDade, Eric , Ghetti, Bernardino , Xiong, Chengjie , Karch, Celeste M. , Schofield, Peter R. , Rossor, Martin N. , Network, Dominantly Inherited Alzheimer, Goate, Alison M , Allegri, Ricardo , Berman, Sarah , Noble, James M

Mayo Clinic

Brain | February 25, 2019 | Volume: 142 | Issue: 5 | Pages: 1429-1440

10.1093/brain/awz050 | PMID 30897203 Get It

Aβ deposition in the basal ganglia is common in autosomal dominant Alzheimer’s disease. Vöglein et al. report an increased severity of motor symptoms in autosomal dominant versus sporadic disease in advanced disease stages. Motor symptoms are more severe in post-codon 200 presenilin 1 mutation carriers and correlate with basal ganglia Aβ.
Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies
Flores, Shaney , Wang, Guoqiao , Hornbeck, Russ C. , Speidel, Benjamin , Joseph‐Mathurin, Nelly , Vlassenko, Andrei G. , Gordon, Brian A. , Klunk, William E. , Jack, Clifford R. , Farlow, Martin R. , Salloway, Stephen , Snider, Barbara J., Berman, Sarah , Roberson, Erik D. , Brosch, Jared R. , Jimenez-Velazques, Ivonne, Dyck, Christopher H. van , Yuan, Shauna H. , Jayadev, Suman , Gauthier, Serge , Hsiung, Ging‐Yuek Robin , Brooks, William S. , Fulham, Michael , Clarnette, Roger, Masters, Colin L. , Wallon, David , Hannequin, Didier , Dubois, Bruno , Pariente, Jérémie , Sánchez‐Valle, Raquel , Mummery, Catherine J. , Ringman, John M. , Klein, Gregory , Milosavljevic‐Ristic, Smiljana, Morris, John C. , Bateman, Randall J. , Jack, Clifford R , Gordon, Brian A , Hsiung, Gink-Yuek , Roberson, Erik , Sánchez-Valle, Raquel , Bateman, Randall J , Masters, Colin L , Joseph-Mathurin, Nelly , Morris, John C , Brooks, William , Su, Yi , Koeppe, Robert A. , Galasko, Douglas , Honig, Lawrence S. , Masellis, Mario , Bottlaender, Michel , McDade, Eric , Xiong, Chengjie , Benzinger, Tammie L.S. , Berman, Sarah

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | February 23, 2019 | Volume: 11 | Issue: 1 | Pages: 180-190

10.1016/j.dadm.2018.12.008 | PMID 30847382 Get It

Abstract Introduction Quantitative in vivo measurement of brain amyloid burden is important for both research and clinical purposes. However, the existence of multiple imaging tracers presents challenges to the interpretation of such measurements. This study presents a direct comparison of Pittsburgh compound B–based and florbetapir‐based amyloid imaging in the same participants from two independent cohorts using a crossover design. Methods Pittsburgh compound B and florbetapir amyloid PET imaging data from three different cohorts were analyzed using previously established pipelines to obtain global amyloid burden measurements. These measurements were converted to the Centiloid scale to allow fair comparison between the two tracers. The mean and inter‐individual variability of the two tracers were compared using multivariate linear models both cross‐sectionally and longitudinally. Results Global amyloid burden measured using the two tracers were strongly correlated in both cohorts. However, higher variability was observed when florbetapir was used as the imaging tracer. The variability may be partially caused by white matter signal as partial volume correction reduces the variability and improves the correlations between the two tracers. Amyloid burden measured using both tracers was found to be in association with clinical and psychometric measurements. Longitudinal comparison of the two tracers was also performed in similar but separate cohorts whose baseline amyloid load was considered elevated (i.e., amyloid positive). No significant difference was detected in the average annualized rate of change measurements made with these two tracers. Discussion Although the amyloid burden measurements were quite similar using these two tracers as expected, difference was observable even after conversion into the Centiloid scale. Further investigation is warranted to identify optimal strategies to harmonize amyloid imaging data acquired using different tracers.
Laminectomy alone versus fusion for grade 1 lumbar spondylolisthesis in 426 patients from the prospective Quality Outcomes Database
Chan, Andrew K. , Bisson, Erica F. , Bydon, Mohamad , Glassman, Steven D. , Foley, Kevin T. , Potts, Eric A. , Shaffrey, Christopher I. , Shaffrey, Mark E., Coric, Domagoj , Knightly, John J. , Park, Paul , Wang, Michael Y. , Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L. , Virk, Michael S., Kerezoudis, Panagiotis , Chotai, Silky , DiGiorgio, Anthony M. , Haid, Regis W., Mummaneni, Praveen V. , Virk, Michael S.

Mayo Clinic

Journal of Neurosurgery: Spine | February 20, 2019 | Volume: 30 | Issue: 2 | Pages: 234-241

10.3171/2018.8.spine17913 | PMID 30544348 Get It

OBJECTIVEThe AANS launched the Quality Outcomes Database (QOD), a prospective longitudinal registry that includes demographic, clinical, and patient-reported outcome (PRO) data to measure the safety and quality of spine surgery. Registry data offer “real-world” insights into the utility of spinal fusion and decompression surgery for lumbar spondylolisthesis. Using the QOD, the authors compared the initial 12-month outcome data for patients undergoing fusion and those undergoing laminectomy alone for grade 1 degenerative lumbar spondylolisthesis.METHODSData from 12 top enrolling sites were analyzed and 426 patients undergoing elective single-level spine surgery for degenerative grade 1 lumbar spondylolisthesis were found. Baseline, 3-month, and 12-month follow-up data were collected and compared, including baseline clinical characteristics, readmission rates, reoperation rates, and PROs. The PROs included Oswestry Disability Index (ODI), back and leg pain numeric rating scale (NRS) scores, and EuroQol–5 Dimensions health survey (EQ-5D) results.RESULTSA total of 342 (80.3%) patients underwent fusion, with the remaining 84 (19.7%) undergoing decompression alone. The fusion cohort was younger (60.7 vs 69.9 years, p < 0.001), had a higher mean body mass index (31.0 vs 28.4, p < 0.001), and had a greater proportion of patients with back pain as a major component of their initial presentation (88.0% vs 60.7%, p < 0.001). There were no differences in 12-month reoperation rate (4.4% vs 6.0%, p = 0.93) and 3-month readmission rates (3.5% vs 1.2%, p = 0.45). At 12 months, both cohorts improved significantly with regard to ODI, NRS back and leg pain, and EQ-5D (p < 0.001, all comparisons). In adjusted analysis, fusion procedures were associated with superior 12-month ODI (β −4.79, 95% CI −9.28 to −0.31; p = 0.04).CONCLUSIONSSurgery for grade 1 lumbar spondylolisthesis—regardless of treatment strategy—was associated with significant improvements in disability, back and leg pain, and quality of life at 12 months. When adjusting for covariates, fusion surgery was associated with superior ODI at 12 months. Although fusion procedures were associated with a lower rate of reoperation, there was no statistically significant difference at 12 months. Further study must be undertaken to assess the durability of either surgical strategy in longer-term follow-up.
Developmental delay, coarse facial features, and epilepsy in a patient with EXT2 gene variants
Gupta, Aditi , Ewing, Sarah, Renaud, Deborah L. , Hasadsri, Linda , Raymond, Kimiyo , Klee, Eric W. , Gavrilova, Ralitza H. , Ewing, Sarah A, Raymond, Kimiyo M

Mayo Clinic

Clinical Case Reports | February 20, 2019 | Volume: 7 | Issue: 4 | Pages: 632-637

10.1002/ccr3.2010 | PMID 30997052 Get It

Key Clinical MessageWe report a patient with developmental delay, autism, epilepsy, macrocephaly, facial dysmorphism, gastrointestinal, and behavioral issues due to EXT2 compound heterozygous likely pathogenic variants. This case report expands the EXT2 gene mutation database and the clinical spectrum of patients with deficiencies in the heparan sulfate pathway.
Impact of Balloon Guide Catheter Use on Clinical and Angiographic Outcomes in the STRATIS Stroke Thrombectomy Registry
Zaidat, Osama O. , Mueller‐Kronast, Nils , Hassan, Ameer E , Jadhav, Ashutosh P. , Froehler, Michael T. , Aziz‐Sultan, Mohammad Ali , Klucznik, Richard , Hellinger, Frank R, Yavagal, Dileep R. , Yao, Tom L., Gupta, Rishi , Martin, Coleman, Bozorgchami, Hormozd, Kaushal, Ritesh , Gandhi, Ravi H. , Peterson, Eric C. , Given, Curtis A., Mehta, Brijesh , Deshmukh, Vivek R., Starkman, Sidney , Linfante, Italo , McPherson, Scott H., Kvamme, Peter , Grobelny, Thomas, Hussain, Muhammad Shazam , Thacker, Ike, Vora, Nirav , Monteith, Stephen J., Ecker, Robert D., Schirmer, Clemens M. , Sauvageau, Eric , Chebl, Alex , Derdeyn, Colin P. , Maidan, Lucian, Badruddin, Aamir , Siddiqui, Adnan H. , Dumont, Travis M., Alhajeri, Abdulnasser, Taqi, Muhammad , Asi, Khaled, Carpenter, Jeffrey , Boulos, Alan S. , Jindal, Gaurav , Puri, Ajit S , Robinson, David , Kallmes, David F. , Baxter, Blaise, Jumaa, Mouhammad , Sunenshine, Peter, Majjhoo, Aniel, English, Joey , Fessler, Richard D., Delgado-Almandoz, Josser, Martin, Jerry C., Liebeskind, David S. , Investigators, on behalf of the STRATIS, Liebeskind, David S. , Siddiqui, Adnan H , Hassan, Ameer E , Schirmer, Clemens M , Jadhav, Ashutosh P , Haussen, Diogo C , Jahan, Reza , Saver, Jeffrey L. , Nogueira, Raul G. , Dashti, Shervin R , Chen, Peng R , Chitale, Rohan V , Deshaies, Eric Michael , Suzuki, Shuichi , Investigators, on behalf of the STRATIS, Derdeyn, Colin P

Mayo Clinic

Stroke | February 19, 2019 | Volume: 50 | Issue: 3 | Pages: 697-704

10.1161/strokeaha.118.021126 | PMID 30776994 Get It

Background and Purpose— Mechanical thrombectomy has been shown to improve clinical outcomes in patients with acute ischemic stroke. However, the impact of balloon guide catheter (BGC) use is not well established. Methods— STRATIS (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) was a prospective, multicenter study of patients with large vessel occlusion treated with the Solitaire stent retriever as first-line therapy. In this study, an independent core laboratory, blinded to the clinical outcomes, reviewed all procedures and angiographic data to classify procedural technique, target clot location, recanalization after each pass, and determine the number of stent retriever passes. The primary clinical end point was functional independence (modified Rankin Scale, 0–2) at 3 months as determined on-site, and the angiographic end point was first-pass effect (FPE) success rate from a single device attempt (modified Thrombolysis in Cerebral Infarction, ≥2c) as determined by a core laboratory. Achieving modified FPE (modified Thrombolysis in Cerebral Infarction, ≥2b) was also assessed. Comparisons of clinical outcomes were made between groups and adjusted for baseline and procedural characteristics. All participating centers received institutional review board approval from their respective institutions. Results— Adjunctive technique groups included BGC (n=445), distal access catheter (n=238), and conventional guide catheter (n=62). The BGC group had a higher rate of FPE following first pass (212/443 [48%]) versus conventional guide catheter (16/62 [26%]; P =0.001) and distal access catheter (83/235 [35%]; P =0.002). Similarly, the BGC group had a higher rate of modified FPE (294/443 [66%]) versus conventional guide catheter (26/62 [42%]; P <0.001) and distal access catheter (129/234 [55%]; P =0.003). The BGC group achieved the highest rate of functional independence (253/415 [61%]) versus conventional guide catheter (23/55 [42%]; P =0.007) and distal access catheter (113/218 [52%]; P =0.027). Final revascularization and mortality rates did not differ across the groups. Conclusions— BGC use was an independent predictor of FPE, modified FPE, and functional independence, suggesting that its routine use may improve the rates of early revascularization success and good clinical outcomes. Clinical Trial Registration— URL: https://www.clinicaltrials.gov . Unique identifier: NCT02239640.
Functional deficiency in endogenous interleukin‐1 receptor antagonist in patients with febrile infection‐related epilepsy syndrome
Clarkson, Benjamin D. , LaFrance‐Corey, Reghann G., Kahoud, Robert J., Farias‐Moeller, Raquel , Payne, Eric T. , Howe, Charles L. , Clarkson, Benjamin D S , Howe, Charles L

Mayo Clinic

Annals of Neurology | February 19, 2019 | Volume: 85 | Issue: 4 | Pages: 526-537

10.1002/ana.25439 | PMID 30779222 Get It

ObjectiveWe recently reported successful treatment of a child with febrile infection‐related epilepsy syndrome (FIRES), a subtype of new onset refractory status epilepticus, with the recombinant interleukin‐1 (IL1) receptor antagonist (IL1RA) anakinra. On this basis, we tested whether endogenous IL1RA production or function is deficient in FIRES patients.MethodsLevels of IL1β and IL1RA were measured in serum and cerebrospinal fluid (CSF). The inhibitory activity of endogenous IL1RA was assessed using a cell‐based reporter assay. IL1RN gene variants were identified by sequencing. Expression levels for the secreted and intracellular isoforms of IL1RA were measured in patient and control cells by real‐time polymerase chain reaction.ResultsLevels of endogenous IL1RA and IL1β were elevated in the serum and CSF of patients with FIRES (n = 7) relative to healthy controls (n = 10). Serum from FIRES patients drove IL1R signaling activity and potentiated IL1R signaling in response to exogenous IL1β in a cell‐based reporter assay. Functional assessment of endogenous IL1RA activity in 3 FIRES patients revealed attenuated inhibition of IL1R signaling. Sequencing of IL1RN in our index patient revealed multiple variants. This was accompanied by reduced expression of intracellular but not secreted isoforms of IL1RA in the patient's peripheral blood mononuclear cells.InterpretationOur findings suggest that FIRES is associated with reduced expression of intracellular IL1RA isoforms and a functional deficiency in IL1RA inhibitory activity. These observations may provide insight into disease pathogenesis for FIRES and other inflammatory seizure disorders and may provide a valuable biomarker for therapeutic decision‐making. Ann Neurol 2019;85:526–537
Canstem111P Trial: A Phase Iii Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine
Sonbol, Mohamad Bassam , Ahn, Daniel H. , Goldstein, David , Tabernero, Josep , Macarulla, Teresa , Reni, Michele , O’Neil, Bert H. , Bekaii‐Saab, Tanios , Sonbol, Mohamad B , Tabernero, Josep , Bekaii-Saab, Tanios S , Okusaka, Takuji , Li, Chung‐Pin , Cutsem, Eric Van , Macarulla, Teresa

Mayo Clinic

Future Oncology | February 15, 2019 | Volume: 15 | Issue: 12 | Pages: 1295-1302

10.2217/fon-2018-0903 | PMID 30768369 Get It

De novo DDX3X missense variants in males appear viable and contribute to syndromic intellectual disability
Nicola, Pantelis , Blackburn, Patrick R. , Rasmussen, Kristen , Bertsch, Nicole L. , Klee, Eric W. , Hasadsri, Linda , Pichurin, Pavel N. , Rankin, Julia, Raymond, F. Lucy , Study, DDD, Clayton‐Smith, Jill, Rasmussen, Kristen J , Study, DDD, Clayton‐Smith, Jill

Mayo Clinic

American Journal of Medical Genetics Part A | February 8, 2019 | Volume: 179 | Issue: 4 | Pages: 570-578

10.1002/ajmg.a.61061 | PMID 30734472 Get It

DDX3X (Xp11.4) encodes a DEAD‐box RNA helicase that escapes X chromosome inactivation. Pathogenic variants in DDX3X have been shown to cause X‐linked intellectual disability (ID) (MRX102, MIM: 300958). The phenotypes associated with DDX3X variants are heterogeneous and include brain and behavioral abnormalities, microcephaly, hypotonia, and movement disorders and/or spasticity. The majority of DDX3X variants described are de novo mutations in females with ID. In contrast, most male DDX3X variants are inherited from an unaffected mother, with one documented exception being a recently identified de novo splice site variant. It has been suggested, therefore, that DDX3X exerts its effects through haploinsufficiency in females, and that affected males carry hypomorphic alleles that retain partial function. Given the lack of male de novo DDX3X variants, loss‐of‐function variants in this gene are suspected to be male lethal. Through whole‐exome sequencing, we identified three unrelated males with hemizygous missense DDX3X variants and ID. All three variants were confirmed by Sanger sequencing, with two established as de novo. In silico analyses were supportive of pathogenicity. We report the male phenotypes and compare them to phenotypes observed in previously reported male and female patients. In conclusion, we propose that de novo DDX3X variants are not necessarily male lethal and should be considered as a cause of syndromic ID in both males and females.
Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy
Ali, Farwa , Martin, Peter R. , Botha, Hugo , Ahlskog, J. Eric , Bower, James H., Masumoto, Joseph Y., Maraganore, Demetrius M. , Hassan, Anhar , Eggers, Scott D.Z. , Drubach, Daniel A., Petersen, Ronald C. , Dunkley, Erika Driver, Gerpen, Jay Van, Uitti, Ryan J. , Whitwell, Jennifer L., Josephs, Keith A. , Eggers, Scott, Drubach, Daniel, Van Gerpen, Jay, Uitti, Ryan, Botha, Hugo , Boeve, Bradley F. , Knopman, David S. , Gerpen, Jay A. van, Whitwell, Jennifer , Dickson, Dennis W.

Mayo Clinic

Movement Disorders | February 6, 2019 | Volume: 34 | Issue: 8 | Pages: 1144-1153

10.1002/mds.27619 | PMID 30726566 Get It

Abstract Background In 2017, the International Parkinson and Movement Disorder Society put forward new clinical criteria for the diagnosis of PSP, recognizing diverse PSP phenotypes. In this study, we compared the sensitivity and specificity of the new criteria with the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria at different times. Methods Patients with clinical parkinsonism, clinical and/or neuropathological diagnosis of PSP, were identified from the Society for Progressive Supranuclear Palsy brain bank. All patients had neuropathologic diagnoses and detailed clinical examination performed by a neurologist at 1 of the 3 Mayo Clinic sites, in Florida, Arizona, and Minnesota. Clinical symptoms and signs were abstracted retrospectively in a blinded fashion and used to determine whether patients met either diagnostic criterion. Patients were divided into early and late disease stage groups using a 3‐year cutoff. Results A total of 129 patients were included, of whom 66 had PSP pathology (51%). The remainder had other neurodegenerative diseases. The overall sensitivity of the International Parkinson and Movement Disorder Society criteria was 87.9%, compared with 45.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria, whereas the specificity of the International Parkinson and Movement Disorder Society probable PSP criteria was 85.7%, compared with 90.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy. Individual patients were noted to have features of multiple PSP phenotypes. Conclusion The International Parkinson and Movement Disorder Society criteria recognize several phenotypes of progressive supranuclear palsy and hence have higher sensitivity than the previous criteria. © 2019 International Parkinson and Movement Disorder Society